PHARMATHER HOLDINGS LTD. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.24 CAD | -2.04% |
|
+14.29% | -23.81% |
| Sales 2022 | - | Sales 2023 | - | Capitalization | 9.7M 13.26M 809M |
|---|---|---|---|---|---|
| Net income 2022 | -4M -5.47M -334M | Net income 2023 | -6M -8.2M -500M | EV / Sales 2022 | - |
| Net cash position 2022 | 12.12M 16.57M 1.01B | Net cash position 2023 | 6.25M 8.55M 521M | EV / Sales 2023 | - |
| P/E ratio 2022 |
-3
x | P/E ratio 2023 |
-1.51
x | Employees | - |
| Yield 2022 * |
-
| Yield 2023 |
-
| Free-Float | 81.31% |
More Fundamentals
* Assessed data
More news
More press releases
| 1 day | -2.04% | ||
| 1 week | +14.29% | ||
| Current month | -38.46% | ||
| 1 month | -27.27% | ||
| 3 months | -5.88% | ||
| 6 months | +92.00% | ||
| Current year | -23.81% |
1 week
0.22
0.26
1 month
0.200.39
Current year
0.170.43
1 year
0.080.43
3 years
0.061.24
5 years
0.051.24
10 years
0.051.24
| Managers | Title | Age | Since |
|---|---|---|---|
Fabio Chianelli
CEO | Chief Executive Officer | - | 01/20/01 |
Carmelo Marrelli
DFI | Director of Finance/CFO | 52 | 01/20/01 |
| Corporate Officer/Principal | - | - |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Beverly Incledon
BRD | Director/Board Member | - | 01/20/01 |
Fabio Chianelli
CEO | Chief Executive Officer | - | 01/20/01 |
Carlo Sansalone
BRD | Director/Board Member | - | 01/20/01 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 26/24/26 | 0.24 | -2.04% | 62,490 |
| 25/24/25 | 0.245 | +4.26% | 28,100 |
| 24/24/24 | 0.235 | +4.44% | 62,264 |
| 23/24/23 | 0.225 | +4.65% | 70,500 |
| 22/24/22 | 0.215 | +2.38% | 28,000 |
Delayed Quote Canadian Securities Exchange, April 27, 2024 at 01:29 am IST
More quotes
PharmaTher Holdings Ltd. is a Canada-based specialty pharmaceutical company. The Company develops and commercializes specialty pharmaceuticals exhibiting growing adoption and permitting delivery methods to enhance patient outcomes. Its lead product is KETARX (racemic ketamine) to fill the global unmet medical needs for anesthesia, sedation, pain, mental health, and neurological indications. The Company is also commercializing PharmaPatch (microneedle patch) with its partners to deliver psychedelics and drugs to treat infectious diseases.
Sector
Pharmaceuticals
Calendar
26/09/2024
- Q4 2024 Earnings Release (Projected)
Quarterly revenue - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| -23.81% | 15.52M | |
| +25.83% | 661B | |
| +27.00% | 566B | |
| -6.76% | 352B | |
| +20.34% | 332B | |
| +3.00% | 283B | |
| +13.09% | 231B | |
| +5.46% | 200B | |
| -9.61% | 195B | |
| -6.26% | 145B |
- Stock Market
- Equities
- PHRM Stock
